Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks ... estimates could grow to become a $800 million-plus product. FDA approval means that Gomekly becomes only the ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

On Monday, Germany-based Merck KGaA (OTC ... Additionally, SpringWorks’ products have the potential to help counter revenue losses from expiring drug patents and increased competition.

Its monotherapy drug that is used to treat desmoid tumors has been approved in the United States. A transaction for Springworks would rank as one of the biggest pharma deals for Merck in recent ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Keytruda & Other Oncology Drugs Drive Merck’s Top Line Merck’s flagship product, Keytruda, generated sales of $7.84 billion in the quarter, up 21%. Sales of the drug benefited from rapid ...